Roche Opens Boston Innovation Center for CVRM Research
BASEL, Switzerland — September 17, 2026 Roche announced the grand opening of the Roche Genentech Innovation Center Boston, expanding...
Roche
Advertisement
Roche Lunsumio Regimen Improves PFS in Follicular Lymphoma
Basel, Switzerland, September 17, 2026 Roche has announced positive results from the Phase III CELESTIMO study, showing that a...
Dualitas Therapeutics and Roche Launch $1B Bispecific Collaboration
SOUTH SAN FRANCISCO, Calif. — September 17, 2026 Dualitas Therapeutics announced a research collaboration and license agreement with Roche...
Genentech Advances Lunsumio in Phase III Follicular Lymphoma
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Genentech announced that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb)...
Genentech Gains FDA Priority Review for Enspryng in MOGAD
SOUTH SAN FRANCISCO, Calif. — September 9, 2026 Genentech, a member of the Roche Group, announced that the U.S....
Advertisements
Roche Wins FDA Priority Review for Enspryng in MOGAD
BASEL, Switzerland — September 10, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Treeline Partners With Roche to Evaluate TLN-121 in Lymphoma
WATERTOWN, Mass., September 2, 2026 Treeline Biosciences, Inc. announced a clinical trial collaboration and supply agreement with Roche to...
Roche Wins FDA Clearance for Elecsys pTau217 Test
INDIANAPOLIS, U.S., Aug 28, 2026 Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based...
Quoin Pharmaceuticals Reports Positive Interim Phase 2/3 Data for QRX003 in Netherton Syndrome
Ashburn, Va. – August 28, 2026 Quoin Pharmaceuticals announced positive interim results from the ongoing Phase 2/3 CL-QRX003-004 study...
Roche’s Vabysmo Enables Extended 20-Week Dosing in PCV Patients
Basel, Switzerland – August 28, 2026 Roche announced new two-year results from the Phase IIIb/IV SALWEEN study evaluating Vabysmo®...
Advertisement
